SCHEMBL6628484

SCHEMBL6628484

Cc1ccncc1-c1nc(Cc2ccc(Cl)cc2)cs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.44
LMNA P02545 3/20 0.40
RAB9A P51151 3/20 0.40
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP17A1 P05093 1/20 0.39
CYP19A1 P11511 2/20 0.39
MAPK1 P28482 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PDE2A O00408 1/20 0.37
PDE10A Q9Y233 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA3 P34903 1/20 0.37
MAPT P10636 3/20 0.37
TP53 P04637 1/20 0.36
NPC1 O15118 2/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6627220 0.99 GFER (0.43) GFERLMNARAB9AKDM4ESMN1; SMN2
SCHEMBL27923764 0.82 GFER (0.61) GFERLMNARAB9AKDM4ESMN1; SMN2
SCHEMBL3814593 0.77 KDM4E (0.66) LMNARAB9AKDM4ESMN1; SMN2CYP19A1
SCHEMBL10284918 0.74 SMN1; SMN2 (0.55) GFERRAB9AKDM4ESMN1; SMN2NPC1
SCHEMBL6626985 0.71 SMN1; SMN2 (0.51) LMNARAB9AKDM4ESMN1; SMN2CYP17A1
SCHEMBL3818666 0.70 CYP19A1 (0.55) LMNARAB9AKDM4ESMN1; SMN2CYP17A1
Hydrochloric Acid SCHEMBL6627345 0.70 SMN1; SMN2 (0.50) LMNARAB9AKDM4ESMN1; SMN2CYP17A1
SCHEMBL6646747 0.70 ALDH1A1 (0.49) LMNARAB9AKDM4ESMN1; SMN2MAPK1
SCHEMBL6645143 0.69 RAB9A (0.58) RAB9AKDM4ESMN1; SMN2CYP17A1CYP19A1
SCHEMBL27923748 0.69 HDAC1 (0.47) GFERLMNARAB9AKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040267017-A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-12-30 US disclosed
EP-1432706-A2 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS Bayer Pharmaceuticals Corporation (US) 2004-06-30 EP disclosed
WO-2003027085-A2 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040267017-A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors CYP17A1, CYP21A2, HSD17B1 GFER 1885/4885LMNA 3233/4885RAB9A 4449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.